Glycaemic control with modified intensive insulin injections (MII) using insulin pens and premixed insulin in

Ashraf T Soliman1, Magdi Omar, Mostafa M Rizk

  • 1Department of Pediatrics, Alexandria University Children's Hospital, El-Chatby, Alexandria, Egypt. ATSOLIMAN@yahoo.com

Insights

Modified intensified insulin therapy (MII) in children with type 1 diabetes improves glycemic control using insulin pens without increasing insulin dosage. This approach offers better blood glucose management compared to conventional therapy, potentially reducing complication risks.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes management in children requires effective strategies for glycemic control.
  • Conventional insulin therapy may not always achieve optimal blood glucose levels.
  • Insulin pens offer a convenient delivery method for intensified insulin regimens.

Purpose of the Study:

  • To compare glycemic control and insulin dosage in children with type 1 diabetes.
  • To evaluate modified intensified insulin therapy (MII) using insulin pens against conventional insulin therapy.
  • To assess the impact of MII on blood glucose, glycated hemoglobin, and total daily insulin dose.

Main Methods:

  • A longitudinal, randomized controlled trial of 6 months or more.
  • Two groups of children with type 1 diabetes were randomly selected: Group AI (n=20) on MII and Group B (n=20) on conventional therapy.
  • Group AII (n=10) with recent diagnosis also received MII.
  • Outcome measures included mean blood glucose, glycated hemoglobin, and total daily insulin dose.

Main Results:

  • Children on MII showed significantly lower mean blood glucose concentrations compared to conventional therapy.
  • Improved glycemic control with MII was achieved without a significant change in average daily insulin dose in Group AI.
  • In Group AII, insulin dosage decreased significantly during the initial 6 months (honeymoon period).

Conclusions:

  • Modified intensified insulin therapy using insulin pens and various insulin formulations provides superior glycemic control in children with type 1 diabetes.
  • This improved control is achievable without increasing insulin requirements.
  • The findings suggest MII could reduce the risk of microvascular complications associated with type 1 diabetes.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...